<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UCL Genetics Institute</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8727124F-2FB8-4EED-9FA2-E27CF658555E"><gtr:id>8727124F-2FB8-4EED-9FA2-E27CF658555E</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:surname>Bertrand</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ014338%2F1"><gtr:id>5EA5F46F-0DB6-4FB0-85D9-ABACBC628F3F</gtr:id><gtr:title>Integrating statistical genetics with nonlinear fixed effect pharmacokinetic models to advance high-throughput personalized drug therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/J014338/1</gtr:grantReference><gtr:abstractText>Pharmacogenetics in pharmacokinetics (PGPK) studies the relationship between variations in DNA sequence on ADME processes and other drug-related outcomes. The European Medicine Agency (EMA) has formally acknowledged the importance of PGPK in a reflection paper in 2007. For example, they recommend the testing of polymorphisms in UGT1A1 and TPMT, which encode enzymes involved in the disposition of irinotecan and mercaptopurine, respectively. In HIV antiretroviral therapy, the CYP2B6 G516T heterozygote and rare homozygote have been found to have 1.4 and 3 times higher concentrations of efavirenz whereas Plasma levels of atazanavir (recently developed protease inhibitor) were shown to be 2.8 and 3.5 higher in patients with the common homozygote than in heterozygotes or rare homozygotes for the MDR1 C3435T variant.

About 30 years ago, nonlinear mixed effects (NLME) models were introduced to the biomedical field and have substantially improved the information learned from preclinical and clinical pharmacokinetic (PK) trials. Indeed, NLME models allow quantification of parameters influencing the complex physiological processes underlying the dose-response relationship. Recently the NLME modelling community has shown a growing interest in multiple single nucleotide polymorphisms (SNPs) analyses. However, the nonlinear structure of the PK models and the potential of association from each SNP to one or more physiological parameters represent great statistical and computational challenges. 

This research project aims at bridging the gap between the analysis of PK data and the growing body of genetics information by integrating the cutting-edge methods developed in genetic statistics into the NLME framework required to handle pharmacokinetic profiles. The computational burden, robustness and power of the statistical methods under study will be assessed on the basis of simulations (aims 1 and 2). Further the statistical developments will be applied to the analysis of PGPK studies performed in both public and industrial projects (aim 3).

This research project will be conducted by Dr. Julie Bertrand under the supervision of Pr. David Balding and involves multiple public and industrial collaborations including the University College London (UCL) in the UK, the French National Agency of research in AIDS (ANRS) in France and the pharmaceutical company Servier in France.</gtr:abstractText><gtr:technicalSummary>Pharmacogenetics in pharmacokinetic (PGPK) studies explore the role of genetics in drug response and hold much promise to provide advances leading to improved patient care, as well as economic benefits to the pharmaceutical industry and to public healthcare providers. In this project we seek to integrate state-of-art statistical genetics with sophisticated statistical modelling.

Most PGPK studies focus on a few single nucleotide polymorphisms (SNPs) that are suspected of being implicated in the drug disposition or effect. We will identify and develop optimal statistical approaches to incorporate a larger set of SNPs into PGPK studies using nonlinear mixed effects (NLME) models. These models allow quantification of parameters influencing the physiological processes, including characterisation of between-subject variability and may take advantage of relatively sparse designs, where many subjects contribute only a limited amount of information.

In work done to date, the multiple SNP penalised regression algorithm, HLASSO (Hoggart et al. 2008), proved more powerful than the commonly used stepwise approach (Lehr et al. 2010) and much faster. Consequently, methods to enrich the genetic information appear feasible in conjunction with an NLME approach. 

First we plan to evaluate other penalised regression algorithms in conjunction with NLME models based on realistic simulations. Then, we will compare the multiple imputations approach coupled with multiple SNP analysis to the haplotype-based alternative to infer on ungenotyped variants in PGPK studies using NLME models (aim 1). In a second stage, we will extend the NLME estimation algorithm to encompass penalized regression on the genetic effect coefficients and evaluate its implementation (aim 2). Finally these developements will be applied to the analysis of a PGPK study on nevirapine conducted in Cambodian HIV patients and PKGK studies from the Servier pharmaceutical company (aim 3).</gtr:technicalSummary><gtr:potentialImpactText>Europe is home to many diverse ethnic communities. London, for example, is believed to be the most ethnically diverse city in the world, with hundreds of languages spoken by lively communities within greater London. As mentioned before pharmacogenetic effects are likely to vary substantially among ethnic groups. Thus, improvements in design and analysis methodology of future pharmacogenetics in pharmacokinetic (PGPK) studies will increase the resource of knowledge and expertise in equitable Health treatment of these diverse ethnic groups which is a major concern to European governments. 

Pharmacogenetics (PG) is becoming a standard component of drug development because of the new guidance for industry on the submission of PG data in clinical drug development issued by the EMA (reflection paper, 2007). Therefore the pharmaceutical industry is bound to beneficiate from methodological advancements in the analysis and design of PGPK studies. Further because her PhD was funded by the partnership of the French Pharmaceutical Industry (Servier) and the National Institute of Health and Medical Research (INSERM) and thanks to the training placements to occur during this project the fellow will be especially likely to meet with the needs and requirements from the industry in terms of PG analyses. Moreover, coping with ethnic diversity will allow the European pharmaceutical industry to be better placed to supply non-European markets.

The fellow has already presented her work to the pharmacological group of the French National Agency of research in AIDS (ANRS). In this area, a network is under development to connect all the materials, competencies and skills in the study of PG data. She is now involved in several projects with leading ANRS researchers, with connections to African and Asian countries where AIDS research is particularly active. The successful completion of the research training under this Fellowship allows her the possibility to take an active part in this network.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>311089</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Phase I study pharmacogenetic analysis for AtsraZeneca</gtr:description><gtr:id>1C63333A-E4EE-474B-BF1C-0DFFBBC66371</gtr:id><gtr:impact>Analysis ongoing, so no output yet.</gtr:impact><gtr:outcomeId>54639aee51a332.45852995-1</gtr:outcomeId><gtr:partnerContribution>Provide PK and genetic data and a priori knowledge on the drug pharmacology</gtr:partnerContribution><gtr:piContribution>Perform the analysis of PK profiles and genetic data using statistical methods I developed : nonlinear mixed effect model based analysis</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CC4FBAF8-1441-4F77-99BF-F3BE0A4F085D</gtr:id><gtr:title>Multiple single nucleotide polymorphism analysis methods in nonlinear mixed-effect pharmacokinetic models</gtr:title><gtr:parentPublicationTitle>RA Fisher Centre</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5463a6a0418816.61156871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B49ECE6-EAA4-4102-B2BF-689B0309B828</gtr:id><gtr:title>Penalized regression implementation within the SAEM algorithm to advance high-throughput personalized drug therapy</gtr:title><gtr:parentPublicationTitle>Population Group Approach in Europe conference</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d8fd9c250d367bf992d4fc3f871a5e"><gtr:id>07d8fd9c250d367bf992d4fc3f871a5e</gtr:id><gtr:otherNames>Julie Bertrand</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>F7ZhZDmRfEE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A31BCB5-C06D-4381-94B6-E5D1AD2572E3</gtr:id><gtr:title>Population approach in high-throughput pharmacogenetics: challenging the maximum likelihood approaches and exploration of a Bayesian alternative</gtr:title><gtr:parentPublicationTitle>PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.  ISSN 1871-6032</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5463a75ae99a53.70688910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E6CFA9C-9D6C-443C-952B-4BD336F52E2F</gtr:id><gtr:title>Bayesian Variable Selection for high-throughput genetic association analysis in population pharmacokinetics.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>18716032</gtr:issn><gtr:outcomeId>56e17606699e96.52098046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CE7F833-C553-46B0-AFAD-25761F1F2A54</gtr:id><gtr:title>Can a Flavored Spray (Pill Glide) Help Children Swallow Their Medicines? A Pilot Study.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21e818f5ae8ab7a6346fd2110ddb5539"><gtr:id>21e818f5ae8ab7a6346fd2110ddb5539</gtr:id><gtr:otherNames>Jagani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>58c6745f4ed128.74183363</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF659E1-891D-4E58-870F-0639A6996A39</gtr:id><gtr:title>Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_14966_26_23337849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A30D84A4-23A8-4CF4-A78C-76B166E0206A</gtr:id><gtr:title>Modeling the pharmacological response to advance the research in pharmacogenetics</gtr:title><gtr:parentPublicationTitle>MRC Biostatistics Unit Centenary Conference</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5463a6f1280650.40159139</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CD25136-A761-4801-B120-A29D1EFFF8A6</gtr:id><gtr:title>CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetics interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial</gtr:title><gtr:parentPublicationTitle>Reviews in Antiviral Therapy &amp; Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/07d8fd9c250d367bf992d4fc3f871a5e"><gtr:id>07d8fd9c250d367bf992d4fc3f871a5e</gtr:id><gtr:otherNames>Julie Bertrand</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>VoAWRnfENLc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>318D99DB-4001-416A-BF0E-8005E1121012</gtr:id><gtr:title>A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59a6a18e7861a47a403759de0d687e20"><gtr:id>59a6a18e7861a47a403759de0d687e20</gtr:id><gtr:otherNames>Reeves S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0160-6689</gtr:issn><gtr:outcomeId>5aaa35b2858327.78992656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DFBD081-F5F8-4FEE-86A9-C9B5DB930FD4</gtr:id><gtr:title>Integrating dynamic mixed-effect modelling and penalized regression to explore genetic association with pharmacokinetics.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>56e172ba792160.81510977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>893D2C7B-17E1-422C-80A7-C451F2942DA6</gtr:id><gtr:title>Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.</gtr:title><gtr:parentPublicationTitle>The AAPS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/426488534efe84d081586a40fc7f92cd"><gtr:id>426488534efe84d081586a40fc7f92cd</gtr:id><gtr:otherNames>Tessier A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1550-7416</gtr:issn><gtr:outcomeId>56e173d8671273.25247645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7948429-B9EA-4961-ADD2-BD2B9462E376</gtr:id><gtr:title>A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59a6a18e7861a47a403759de0d687e20"><gtr:id>59a6a18e7861a47a403759de0d687e20</gtr:id><gtr:otherNames>Reeves S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>58c6745f1e0833.63611350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DADBE0FF-4AD2-4AAE-9A70-D7FDD388E1A3</gtr:id><gtr:title>Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2cbfc0243e2033ae46e6305c877b853"><gtr:id>e2cbfc0243e2033ae46e6305c877b853</gtr:id><gtr:otherNames>Eloy P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5aaa35b24e8bd4.42885123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D13184D2-0008-4554-B802-366A6962B381</gtr:id><gtr:title>Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/045cffd6f851e3023d782432b2084283"><gtr:id>045cffd6f851e3023d782432b2084283</gtr:id><gtr:otherNames>Bertrand J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_14966_26_23990572</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J014338/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>